Basic Info
  • Grade: Pharmaceutical Grade

    Factory Location: Taizhou, Zhejiang, P.R.China

    Main Sales Markets: Eastern Europe,Asia,Middle East,Africa

  • Monthly Production Capacity: TBC

    Contract Manufacturing: CRO,CMO

  • Sample Provided: no

    Payment Terms: T/T

    In 2014, favipiravir was approved in Japan to treat cases of influenza that were unresponsive to conventional treatment. Given its efficacy at targetting several strains of influenza, it has been investigated in other countries to treat novel viruses including Ebola and most recently, COVID-19.

Send your message to this supplier
  • From:
  • To:
    ZHEJIANG HISUN PHARMACEUTICAL CO.,LTD.
  • Send a Copy to this Email
  • Message:
    Upload Images / Files
    - Supports jpg, jpeg, png,
     gif, pdf, doc, docx,
     xls, xlsx, txt, rar and zip
    - Max upload 3 files;
     Max  total size: 3MB
    (0/3)

    Enter between 20 to 4,000 characters.This is not what you are looking for ? Post a Sourcing Request Now

  • Verification:
PharmaSources Customer Service